470 Matching Results

Search Results

Advanced search parameters have been applied.

The Controlled Substances Act: Regulatory Requirements

Description: This report highlights certain non-criminal regulatory requirements of the Controlled Substances Act (CSA). The CSA and its implementing regulations establish a framework through which the federal government regulates the use of controlled substances for legitimate medical, scientific, research, and industrial purposes, and prevents these substances from being diverted for illegal purposes.
Date: unknown
Creator: Nichols, James E. & Yeh, Brian T.
Partner: UNT Libraries Government Documents Department

Legal Issues Relating to the Disposal of Dispensed Controlled Substances

Description: This report describes an issue that is the fastest-growing drug problem in the country -- the intentional use of prescription drugs for non-medical purposes. It is the second-most common form of illicit drug abuse among teenagers in the United States behind marijuana use. Several bills have been introduced in the 111th Congress that would create a legal framework governing disposal of controlled substances that have been dispensed to patients.
Date: September 24, 2010
Creator: Yeh, Brian T.
Partner: UNT Libraries Government Documents Department

Legal Issues Relating to the Disposal of Dispensed Controlled Substances

Description: Prescription drug abuse is the second-most common form of illicit drug abuse among teenagers in the United States, trailing only marijuana use. Prescription drug abuse has become a particular concern amongst federal policymakers. This report discusses this issue, including related pieces of legislation such as the Controlled Substances Act, the Secure and Responsible Drug Disposal Act of 2010, and the proper way to dispose of controlled substances.
Date: October 19, 2010
Creator: Yeh, Brian T.
Partner: UNT Libraries Government Documents Department

Active Opioid Legislation in the House: In Brief

Description: This report briefly summarizes opioid-related bills that were considered during "Opioid Week" (the week of May 9, 2016) The summaries in this report may be useful illustrations of the range of approaches Members of Congress have proposed to address the problem of opioid addiction.
Date: May 13, 2016
Creator: Bagalman, Erin; Sacco, Lisa N. & Rosen, Liana W.
Partner: UNT Libraries Government Documents Department

Medicare: Enrollment in Medicare Drug Plans

Description: This report discusses the enrollment process for private prescription drug plans (PDPs) or Medicare Advantage prescription drug (MA-PD) plans. At a minimum, these plans offer "standard coverage" or alternative coverage with actuarially equivalent benefits. Beneficiaries are required to enroll in one of these private plans in order to obtain coverage.
Date: January 3, 2006
Creator: O'Sullivan, Jennifer
Partner: UNT Libraries Government Documents Department

Pharmaceutical Supply Chain Security

Description: This report serves as a primer on pharmaceutical supply chain issues. It (1) describes the chain from manufacturer to patient, including where it is vulnerable; (2) summarizes current federal law, regulation, and FDA policies that Congress and the agency designed to protect the integrity of the final drug product, and indicates where those protections may falter; (3) notes state-level and professional association activities; and (4) discusses areas that Congress, FDA, and industry, health care, and patient stakeholders have suggested might be changed to increase the security of the pharmaceutical supply chain.
Date: October 31, 2013
Creator: Thaul, Susan
Partner: UNT Libraries Government Documents Department

Medicare: Enrollment in Medicare Drug Plans

Description: This report discusses the enrollment process for private prescription drug plans (PDPs) or Medicare Advantage prescription drug (MA-PD) plans. At a minimum, these plans offer "standard coverage" or alternative coverage with actuarially equivalent benefits. Beneficiaries are required to enroll in one of these private plans in order to obtain coverage.
Date: October 20, 2006
Creator: O'Sullivan, Jennifer
Partner: UNT Libraries Government Documents Department

Medicare Prescription Drug Benefit: Low-Income Provisions

Description: This report begins by providing an overview of Medicare Prescription Drug, Improvement and Modernization Act of 2003 (MMA) benefits, including premium and cost-sharing liabilities for the general Medicare population. The overview is followed by a discussion of the subsidy benefits available for low-income individuals. The report then highlights some of the key implementation issues.
Date: June 1, 2006
Creator: O’Sullivan, Jennifer
Partner: UNT Libraries Government Documents Department

Synthetic Drugs: Overview and Issues for Congress

Description: This report discusses the federal scheduling of controlled substances, including the temporary scheduling of substances. It also provides an overview of current trends in selected synthetic cannabinoids and stimulants. It concludes with a review of relevant legislation as well as possible issues policymakers might consider.
Date: May 3, 2016
Creator: Sacco, Lisa N. & Finklea, Kristin
Partner: UNT Libraries Government Documents Department

Synthetic Drugs: Overview and Issues for Congress

Description: This report discusses the federal scheduling of controlled substances, including the temporary scheduling of substances. It also provides an overview of current trends in selected synthetic cannabinoids and stimulants. It concludes with a review of relevant legislation as well as possible issues policymakers might consider.
Date: September 16, 2013
Creator: Sacco, Lisa N. & Finklea, Kristin M.
Partner: UNT Libraries Government Documents Department

Synthetic Drugs: Overview and Issues for Congress

Description: This report discusses the federal scheduling of controlled substances, including the temporary scheduling of substances. It also provides an overview of current trends in selected synthetic cannabinoids and stimulants. It concludes with a review of selected relevant legislation in the 112th Congress as well as issues for policymakers to consider.
Date: October 28, 2011
Creator: Sacco, Lisa N. & Finklea, Kristin M.
Partner: UNT Libraries Government Documents Department

Compounded Drugs

Description: This report provides background information on compounded drugs (CDs) and nontraditional compounding pharmacies relevant to policy discussions. This includes an overview of the 2012 fungal meningitis outbreak; recent recalls of compounded drugs; definitions of traditional compounding and nontraditional compounding; information on the CDs produced and by whom; information on the demand for nontraditional compounding, including the role of shortages of sterile injectable drugs, hospital outsourcing, and patient and provider demand; and information on adverse events involving compounded drugs.
Date: May 23, 2013
Creator: Glassgold, Judith M.
Partner: UNT Libraries Government Documents Department

Drug Labeling in Developing Countries

Description: This report discusses the pharmaceutical labeling requirements imposed on U.S.-based companies by the laws of the United States and the barriers to U.S. regulation of their labeling in other countries.
Date: February 1993
Creator: United States. Congress. Office of Technology Assessment.
Partner: UNT Libraries Government Documents Department

Hydantoins as Anticonvulsants. VIII. 5-Alkylmercapto Derivatives of 3-Methyl-5-Phenylhydantoin

Description: Recent years have seen a rapid increase in the search for new compounds to be employed in the treatment of convulsions associated with epilepsy and related ailments. The properties desired are a higher degree of effectiveness and lower toxicity than those already in use. This thesis describes the effect of methylation of the 5-alkylmercapto-5-phenylhydantoins.
Date: January 1954
Creator: Dick, Clarence Reinhardt
Partner: UNT Libraries

Identification and Characterization of a Calcium/Phospholipid-Dependent Protein Kinase in P1798 Lymphosarcomas

Description: Calcium/phospholipid-dependent protein kinase (PKC) was partially purified from P1798 lymphosarcoma. Phospholipid-dependence was specific for phosphatidylserine. PKC phosphorylated Histone 1, with an apparent K_m of 14.1 μM. Chlorpromazine, a lipid-binding drug, inhibited PKC activity by 100%. Further studies were undertaken to establish analytical conditions which could be applied to the study of PKC in intact cells. The conditions included (1) determining optimum cell concentration for measuring PKC activity, (2) recovering PKC into the soluble fraction of cell extracts, (3) evaluating calcium and phospholipid requirements of PKC in this fraction, and (4) inhibiting PKC in this fraction. Final studies involved treatment of intact cells with potential activators. Both phytohaemagglutinin and a phorbol ester increased PKC activation.
Date: May 1984
Creator: Magnino, Peggy E. (Peggy Elizabeth)
Partner: UNT Libraries

2016 Rio Games: Anti-Doping Testing

Description: This report discusses the the anti-doping testing program during the 2016 Summer Olympics. Responsibility for the rests with the International Olympic Committee (IOC). The testing period began July 24, 2016, when the Olympic village opened, and continues through August 21, 2016, the date of the closing ceremony.
Date: August 3, 2016
Creator: Halchin, L. E.
Partner: UNT Libraries Government Documents Department

Drug Retention Times

Description: The purpose of this monograph is to provide information on drug retention times in the human body. The information provided is based on plausible illegal drug use activities that might be engaged in by a recreational drug user
Date: May 1, 2007
Creator: Studies, Center for Human Reliability
Partner: UNT Libraries Government Documents Department

Drug Enforcement in the United States: History, Policy, and Trends

Description: This report reviews federal domestic drug enforcement. First, it provides a history and background of drug enforcement in the United States including how drugs came under the control of federal justice authorities and how legislation and administrative actions changed domestic drug enforcement. It then provides a brief overview of drug enforcement in the United States and summarizes U.S. drug policy. Finally, the report presents trends in federal drug enforcement and concludes with a discussion of drug enforcement issues going forward.
Date: October 2, 2014
Creator: Sacco, Lisa N.
Partner: UNT Libraries Government Documents Department

Animal Drug User Fee Programs

Description: This report discusses aspects of the Animal Drug User Fee Act of 2003 (ADUFA I), including funding and program performance; the Food and Drug Administration's (FDA) ADUFA II and Animal Generic Drug User Fee Act of 2008 (AGDUFA) proposals; congressional activity; and other relevant issues.
Date: August 4, 2008
Creator: Lister, Sarah A.
Partner: UNT Libraries Government Documents Department